| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
HER2/neu (654-662) GP2 targets HER2/neu-expressing cancer cells through the induction of HLA-A2-restricted cytotoxic T lymphocytes (CTL). The peptide is derived from the HER2/neu protein, which is overexpressed in various epithelial cancers including breast, ovarian, and gastric cancers. By inducing CTL responses, the peptide enables immune-mediated killing of HER2/neu-expressing tumor cells.
|
|---|---|
| ln Vitro |
HER2/neu (654-662) GP2 demonstrates in vitro activity by inducing HLA-A2-restricted cytotoxic T lymphocytes that are reactive to various epithelial cancers. The peptide effectively stimulates CTL responses in HLA-A2-positive immune cells. These CTLs can recognize and kill HER2/neu-expressing tumor cells. The peptide is used in studies of peptide-based cancer vaccines and immunotherapy.
|
| ln Vivo |
In vivo, HER2/neu (654-662) GP2 has been studied as a cancer vaccine peptide for inducing immune responses against HER2/neu-expressing tumors. The peptide induces HLA-A2-restricted CTL responses that can recognize and kill HER2/neu-expressing cancer cells. GP2 has been investigated in clinical trials for cancer immunotherapy. The peptide shows potential for use in peptide-based vaccines.
|
| Enzyme Assay |
In vitro T cell stimulation assays for HER2/neu (654-662) GP2 involve culturing HLA-A2-positive peripheral blood mononuclear cells (PBMCs) or T cells with the peptide. Cells are stimulated with varying concentrations of the peptide (typically 1-100 microg/mL) for 7-14 days, with IL-2 supplementation. CTL activity is assessed by chromium release assay or IFN-gamma ELISpot against HER2/neu-expressing target cells. Peptide-MHC binding affinity may be assessed by MHC stabilization assays.
|
| Cell Assay |
Cellular assays for HER2/neu (654-662) GP2 involve using HLA-A2-positive antigen-presenting cells pulsed with the peptide to stimulate T cell responses. Readouts include T cell proliferation measured by 3H-thymidine incorporation or CFSE dilution, IFN-gamma production by ELISA or ELISpot, and cytotoxic activity against HER2/neu-expressing target cells. The peptide's ability to induce CTL responses specific for HER2/neu is confirmed.
|
| Animal Protocol |
In vivo animal studies for HER2/neu (654-662) GP2 typically employ HLA-A2 transgenic mouse models or humanized mouse models bearing HER2/neu-expressing tumors. Mice are immunized with the peptide (typically with adjuvant) and challenged with tumor cells. Tumor growth inhibition, CTL responses, and survival are monitored. The peptide's ability to induce protective immunity against HER2/neu-expressing tumors is assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for HER2/neu (654-662) GP2 is characteristic of peptide-based therapeutics. The peptide is typically administered via subcutaneous or intradermal injection, often with adjuvant. PK parameters including absorption, distribution, and elimination are determined via ELISA or LC-MS. The peptide's small size (9 amino acids) may result in rapid clearance. Stability in biological fluids is assessed. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for HER2/neu (654-662) GP2 is characteristic of peptide-based immunotherapies. Potential toxicities include immune-related adverse events due to CTL activation. The peptide has been studied in clinical trials with acceptable safety profiles. Standard laboratory safety precautions should be observed during handling. The compound is for research use only.
|
| References | |
| Additional Infomation |
The GP2 peptide is being studied in the clinical trial NCT00524277 (vaccine therapy for breast cancer patients).
HER2/neu (654-662) GP2 (CAS# 160790-21-6) is a nine-amino-acid peptide derived from HER2/neu. It induces HLA-A2-restricted cytotoxic T lymphocytes reactive to various epithelial cancers. GP2 has been investigated in clinical trials as a cancer vaccine peptide. The peptide is used in cancer immunotherapy research. It is not approved for routine clinical use. The compound is for research purposes only. |
| Molecular Formula |
C42H77N9O11
|
|---|---|
| Molecular Weight |
884.1145
|
| Exact Mass |
883.574
|
| CAS # |
160790-21-6
|
| PubChem CID |
448183
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.244
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
62
|
| Complexity |
1530
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)O)N
|
| InChi Key |
XQIXDDUJIUUELO-JZOOTMHBSA-N
|
| InChi Code |
InChI=1S/C42H77N9O11/c1-14-23(10)30(43)37(56)51-34(25(12)16-3)41(60)47-28(19-52)36(55)45-26(13)35(54)49-32(22(8)9)39(58)50-31(21(6)7)38(57)44-18-29(53)48-33(24(11)15-2)40(59)46-27(42(61)62)17-20(4)5/h20-28,30-34,52H,14-19,43H2,1-13H3,(H,44,57)(H,45,55)(H,46,59)(H,47,60)(H,48,53)(H,49,54)(H,50,58)(H,51,56)(H,61,62)/t23-,24-,25-,26-,27-,28-,30-,31-,32-,33-,34-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S,3S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1311 mL | 5.6554 mL | 11.3108 mL | |
| 5 mM | 0.2262 mL | 1.1311 mL | 2.2622 mL | |
| 10 mM | 0.1131 mL | 0.5655 mL | 1.1311 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
